Hughes Brittany N, Jorgensen Kirsten A, Cummings Shelly, Morah Damini, Krause Kate, Rauh-Hain Jose Alejandro, Herzog Thomas J
University of Cincinnati Cancer Center, Cincinnati, Ohio, USA
Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center Division of Surgery, Houston, Texas, USA.
Int J Gynecol Cancer. 2023 Feb 6;33(2):250-256. doi: 10.1136/ijgc-2022-003913.
Identification of persons at risk for hereditary syndromes through genetic testing prior to cancer diagnosis may proactively reduce the cancer burden morbidity and mortality. Using a framework of health equity, this study characterizes the global landscape of publication and reference to genetic testing guidelines (GTG).
This study used a systematic literature search supplemented by an International Gynecologic Cancer Society (IGCS) informal survey and cross referenced with Myriad Genetics records, to identify published GTG, their country of origin, and countries referencing them.
Of 1011 identified publications, 166 met the inclusion criteria, from which 46 unique guidelines were identified, published by 18 countries and two regions (Europe and the UK). Authorship from the USA accounted for 63% of publications on GTG. Systematic mapping reviews revealed 34 countries with published and/or referenced guidelines, the IGCS survey revealed 22 additional countries, and coordination with Myriad Genetics revealed additional information for two countries and primary information for one country. Of the 57 countries evaluated, 33% published their own guidelines and reference guidelines from another country/region, 5% published their own guidelines without referencing another country/region, and 61% only referenced a guideline from another country/region. No data were available for 138 of 195 countries, disproportionately from Africa, the Middle East, Eastern Europe, and Southeast Asia.
Global geographic disparities in the publication and referencing of GTG exist, with a large emphasis on North American and European guidelines in the published literature. These disparities highlight a need for uniform GTG to improve global health equity.
在癌症诊断前通过基因检测识别遗传性综合征的高危人群,可能会积极降低癌症负担、发病率和死亡率。本研究采用健康公平框架,描述了全球基因检测指南(GTG)的发表情况及引用情况。
本研究采用系统文献检索,并辅以国际妇科癌症协会(IGCS)的非正式调查,并与Myriad Genetics记录进行交叉引用,以识别已发表的GTG、其原产国以及引用它们的国家。
在1011篇已识别的出版物中,166篇符合纳入标准,从中识别出46项独特的指南,由18个国家和两个地区(欧洲和英国)发表。美国作者撰写的关于GTG的出版物占63%。系统映射综述显示有34个国家发表和/或引用了指南,IGCS调查又揭示了22个国家,与Myriad Genetics的协调揭示了另外两个国家的补充信息和一个国家的主要信息。在评估的57个国家中,33%发表了自己的指南并引用了其他国家/地区的参考指南,5%只发表了自己的指南而未引用其他国家/地区的指南,61%只引用了其他国家/地区的指南。195个国家中有138个没有数据,这些国家主要来自非洲、中东、东欧和东南亚。
GTG的发表和引用存在全球地理差异,已发表的文献中大量强调北美和欧洲的指南。这些差异凸显了需要统一的GTG来改善全球健康公平。